National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

tranexamic acid
A synthetic derivative of the amino acid lysine with antifibrinolytic activity. With strong affinity for the five lysine-binding sites of plasminogen, transexamic acid competitively inhibits the activation of plasminogen to plasmin, resulting in inhibition of fibrinolysis; at higher concentrations, this agent noncompetitively inhibits plasmin. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Cyklokapron



Previous:tositumomab and iodine I 131 tositumomab, Totect, tozasertib lactate, TPI 287, trabectedin
Next:transdermal estrogen, transferrin receptor-targeted anti-RRM2 siRNA CALAA-01, transferrin receptor-targeted liposomal p53 cDNA, transferrin-CRM107, transgenic lymphocyte immunization vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov